Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $609000.0.

  • Keros Therapeutics' Amortizatization of Intangibles rose 817.05% to $609000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 4908.4%. This contributed to the annual value of $1.8 million for FY2024, which is 1726.8% up from last year.
  • As of Q3 2025, Keros Therapeutics' Amortizatization of Intangibles stood at $609000.0, which was up 817.05% from $595000.0 recorded in Q2 2025.
  • Keros Therapeutics' Amortizatization of Intangibles' 5-year high stood at $609000.0 during Q3 2025, with a 5-year trough of $99000.0 in Q1 2021.
  • In the last 5 years, Keros Therapeutics' Amortizatization of Intangibles had a median value of $339000.0 in 2024 and averaged $348473.7.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 15714.29% in 2023, then plummeted by 3505.75% in 2024.
  • Over the past 5 years, Keros Therapeutics' Amortizatization of Intangibles (Quarter) stood at $198000.0 in 2021, then soared by 62.12% to $321000.0 in 2022, then rose by 4.36% to $335000.0 in 2023, then soared by 70.75% to $572000.0 in 2024, then grew by 6.47% to $609000.0 in 2025.
  • Its Amortizatization of Intangibles was $609000.0 in Q3 2025, compared to $595000.0 in Q2 2025 and $584000.0 in Q1 2025.